This is a working overview of refrigeration, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-03. Anything still debated is marked as such rather than presented as settled.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Killed Arpad Horvath (75) at Meadow Park facility in London, Ontario Injected Sandra Towler (77) "with intent to murder" at a retirement home in Paris, Ontario Injected Beverly Bertram (68) "with intent to murder" at a private residence in Ingersoll, Ontario
=== EC 1.14.18 With another compound as one donor, and incorporation of one atom of oxygen into the other donor === EC 1.14.18.1: tyrosinase EC 1.14.18.2: CMP-N-acetylneuraminate monooxygenase EC 1.14.18.3: methane monooxygenase (particulate) EC 1.14.18.4: phosphatidylcholine 12-monooxygenase EC 1.14.18.5: sphingolipid C4-monooxygenase EC 1.14.18.6: 4-hydroxysphinganine ceramide fatty acyl 2-hydroxylase EC 1.14.18.7: dihydroceramide fatty acyl 2-hydroxylase EC 1.14.18.8: Now included with EC 1.14.14.139, 5β-cholestane-3α,7α-diol 12α-hydroxylase EC 1.14.18.9: 4α-methylsterol monooxygenase EC 1.14.18.10: plant 4,4-dimethylsterol C-4α-methyl-monooxygenase EC 1.14.18.11: plant 4α-monomethylsterol monooxygenase EC 1.14.18.12: 2-hydroxy fatty acid dioxygenase
== Relationship to other South Asians and West Asians == A 1985 study conducted by Roychoudhury AK and Nei M indicating the values of genetic distance showed that the Sinhalese, along with the four Indian subcontinent populations from Punjab, Gujarat, Andhra Pradesh, and Bangladesh, were closer to Afghans and Iranians than the neighboring East/Southeast Asian groups represented by the Bhutanese, Malays, Bataks in northern Sumatra, and the Chinese.
MVT-602 (other developmental code names RVT-602, TAK-448) is a kisspeptin receptor agonist which is under development for the treatment of female infertility and hypogonadism. It has been found to increase luteinizing hormone levels in premenopausal women. As of March 2021, MVT-602 is in phase 2 clinical trials for the treatment of female infertility and hypogonadism. It was also under development for the treatment of prostate cancer, but development for this indication was discontinued.
Sources: en.wikipedia.org
== Protein classification == Proteins may be classified according to both structural and sequential similarity. For structural classification, the sizes and spatial arrangements of secondary structures described in the above paragraph are compared in known three-dimensional structures. Classification based on sequence similarity was historically the first to be used. Initially, similarity based on alignments of whole sequences was performed. Later, proteins were classified on the basis of the occurrence of conserved amino acid patterns. Databases that classify proteins by one or more of these schemes are available. In considering protein classification schemes, it is important to keep several observations in mind. First, two entirely different protein sequences from different evolutionary origins may fold into a similar structure. Conversely, the sequence of an ancient gene for a given structure may have diverged considerably in different species while at the same time maintaining the same basic structural features. Recognizing any remaining sequence similarity in such cases may be a very difficult task. Second, two proteins that share a significant degree of sequence similarity either with each other or with a third sequence also share an evolutionary origin and should share some structural features also. However, gene duplication and genetic rearrangements during evolution may give rise to new gene copies, which can then evolve into proteins with new function and structure.
where J0(λnr/R) is the Bessel function of the first kind of order zero and λn are the positive roots of this function and J1(λn) is the Bessel function of the first kind of order one. As t → ∞, Poiseuille solution is recovered.
=== Cryopreserved red blood cells === To increase the availability of RBCs of rare blood types, red blood cells can be stored cryopreserved (frozen) instead of refrigerated. With a controlled, standardised freezing and thawing process, the red blood cells can be stored in frozen condition for up to 30 years. Also for cryopreservation, cell processors are frequently used for both the pre-freezing glycerolisation procedure and for washing away the glycerol after thawing of the red blood cells. Using an automated device allows for standardised processing to ensure optimal protection from ice crystal formation, which otherwise could damage the red blood cells. There are two general approaches for RBC cryopreservation, referred to as the high- and the low-glycerol method. Glycerol serves as cryoprotectant in both. The high-glycerol method uses 40% weight/volume glycerol, a slow freezing rate (1–3 °C per minute) and allows storage of the frozen red blood cells in common mechanical −60–80 °C freezers. The low-glycerol method is based on 20% weight/volume glycerol and demands plunge freezing in (−150 °C) liquid nitrogen. Because of the extreme storage temperature, the low-glycerol method is not compatible with the PVC tubes of blood bags. PVC tubes are essential for sterile docking; a technology which maintains a closed system after thawing and, thereby, allows a longer post-thawing shelf-life.
=== Cardiac muscle === Cardiac muscle is slightly different from skeletal muscle. At rest, they prefer to utilize fatty acids as their main energy source. As activity increases and it begins to pump faster, the cardiac muscles begin to oxidize glucose at a higher rate. An analysis of mRNA levels of GLUT1 and GLUT4 in cardiac muscles show that GLUT1 plays a larger role in cardiac muscles than it does in skeletal muscles. GLUT4, however, is still believed to be the primary transporter for glucose. Much like in other tissues, GLUT4 also responds to insulin signaling, and is transported into the plasma membrane to facilitate the diffusion of glucose into the cell.
Actin plays a particularly prominent role in muscle cells, which consist largely of repeated bundles of actin and myosin II. Each repeated unit – called a sarcomere – consists of two sets of oppositely oriented F-actin strands ("thin filaments"), interlaced with bundles of myosin ("thick filaments"). The two sets of actin strands are oriented with their (+) ends embedded in either end of the sarcomere in delimiting structures called Z-disks. The myosin fibrils are in the middle between the sets of actin filaments, with strands facing in both directions. When the muscle contracts, the myosin threads move along the actin filaments towards the (+) end, pulling the ends of the sarcomere together and shortening it by around 70% of its length. In order to move along the actin thread, myosin must hydrolyze ATP; thus ATP serves as the energy source for muscle contraction. At times of rest, the proteins tropomyosin and troponin bind to the actin filaments, preventing the attachment of myosin. When an activation signal (i.e. an action potential) arrives at the muscle fiber, it triggers the release of Ca2+ from the sarcoplasmic reticulum into the cytosol. The resulting spike in cytosolic calcium rapidly releases tropomyosin and troponin from the actin thread, allowing myosin to bind, and muscle contraction to begin.
Sources: en.wikipedia.org
The 1960s saw extensive research into the synthesis of hydroquinone from acetylene and carbon monoxide via catalytic iron pentacarbonyl. Rhodium or ruthenium can substitute for iron as the catalyst with favorable chemical yields, but are not typically used due to the cost of recovery from the reaction mixture. Hydroquinone and its derivatives can also be prepared by oxidation of various electron-rich benzene derivatives, such as phenols, aniline, and DIPB. Examples include Elbs persulfate oxidation and Dakin oxidation. Hydroquinone was first obtained in 1820 by the French chemists Pelletier and Caventou via the dry distillation of quinic acid. Hydrolysis of chlorophenol. The latter two methods are generally less atom-economical than oxidation with hydrogen peroxide, as are certain industrial implementations of the peroxide oxidation. Their commercial practice in China produced serious pollution in 2022.
=== Bulgarian === The Bulgarian online etymological dictionary claims that longest word in Bulgarian to be the 39-letter-long непротивоконституционствувателствувайте (neprotivokonstitutsionstvuvatelstvuvayte), introduced in the Constitution of Bulgaria of 1947 (Dimitrov Constitution). The word means "do not perform actions against the constitution" (addressed to more than one person).
== History == The Laténium is the biggest archaeological museum in Switzerland. The permanent exhibition features around 3000 objects coming from excavations mostly realised in the Canton of Neuchâtel. These objects are picked from the 525000 pieces that form the museum's collections and span 50'000 years of Europe's past.
The precursor to indigo is indican, a colorless, water-soluble derivative of the amino acid tryptophan, and Indigofera leaves contain as much as 0.2–0.8% of this compound. Pressing cut leaves into a vat and soaking hydrolyzes the indican, releasing β-D-glucose and indoxyl. The indoxyl dimerizes in the mixture, and after 12–15 hours of fermentation yields the yellow, water-soluble leucoindigo. Subsequent exposure to air forms the blue, water-insoluble indigo dye. The dye precipitates from the fermented leaf solution upon oxidation, but may also be precipitated when mixed with a strong base such as lye. The solids are filtered, pressed into cakes, dried, and powdered. The powder is then mixed with various other substances to produce different shades of blue and purple. Natural sources of indigo also include mollusks: the Murex genus of sea snails produces a mixture of indigo and 6,6'-dibromoindigo (red), which together produce a range of purple hues known as Tyrian purple. Light exposure during part of the dyeing process can convert the dibromoindigo into indigo, resulting in blue hues known as royal blue, hyacinth purple, or tekhelet.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.